...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Materials science & engineering >Doxorubicin eluting microporous polysaccharide scaffolds: An implantable device to expunge tumour
【24h】

Doxorubicin eluting microporous polysaccharide scaffolds: An implantable device to expunge tumour

机译：阿霉素洗脱微孔多糖支架：一种可植入的清除肿瘤的装置

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A variety of naturally derived and synthetic biomaterial scaffolds have been investigated as 3D environments for supporting cell growth and can be used to achieve drug delivery with high loading efficiency. Polysaccharides which enhance the tumour-specific drug release are ideal candidates for scaffold preparation in combination with chemotherapeutic agents for the management of solid tumours by local applications. Galactoxyloglucan (PST001) based porous scaffolds (PS) were prepared by crosslinking and freeze drying with a porosity of 90%. FTIR showed the same functional groups as of PST001 with slight peak shifts and 1200% water absorption was observed. Comparing with PBS, macrophage mediated improved degradation up to 40% in 28 days was observed. The scaffold was relatively non toxic towards normal and cancer cells and there was no epithelial mesenchymal transition (EMT) observed. In vitro drug release profile of doxorubicin (DOX)-loaded scaffold (PSD) showed higher release at acidic pH, apparent in tumour microenvironment, than normal physiological pH. In in vitro assays, cell viability was decreased confirming the drug release potential of the scaffold. DLA tumour was significantly reduced with PSD implantation. The excellent biodegradability of the PS overcome the limitations of non-biodegradable systems which support the sustained release of the drug and degrade after a specific time period. The local tumour reduction potential of the PSD embrace immense application in malignant solid tumour management.
机译：已经研究了多种天然来源的和合成的生物材料支架作为支持细胞生长的3D环境，可用于实现高负载效率的药物递送。增强肿瘤特异性药物释放的多糖是用于支架制备的理想候选物，结合化学治疗剂用于通过局部应用来治疗实体瘤。通过交联和冷冻干燥以90％的孔隙率制备基于半乳糖基葡聚糖（PST001）的多孔支架（PS）。 FTIR显示与PST001相同的官能团，但有轻微的峰位移，并且观察到1200％的吸水率。与PBS相比，在28天内观察到巨噬细胞介导的降解改善高达40％。该支架对正常细胞和癌细胞无毒，并且未观察到上皮间质转化（EMT）。载有阿霉素（DOX）的支架（PSD）的体外药物释放曲线显示，在酸性pH下（在肿瘤微环境中明显）释放的释放高于正常的生理pH。在体外测定中，细胞活力降低，证实了支架的药物释放潜力。 PSD植入可显着减少DLA肿瘤。 PS的出色的生物降解性克服了不可生物降解系统的局限性，后者支持药物的持续释放并在特定时间段后降解。 PSD的局部减少肿瘤的潜力在恶性实体瘤治疗中具有广阔的应用前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号